We are live on ! Find out more
RAPT

RAPT Therapeutics

Delisted

RAPT was delisted on the 2nd of March, 2026.

105 hedge funds and large institutions have $1.02B invested in RAPT Therapeutics in 2025 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 36 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,387% more call options, than puts

Call options by funds: $22.1M | Put options by funds: $295K

513% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 8

300% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 9

139% more capital invested

Capital invested by funds: $428M → $1.02B (+$594M)

62% more funds holding

Funds holding: 65105 (+40)

9.04% more ownership

Funds ownership: 100.35%109.39% (+9%)

0% more funds holding in top 10

Funds holding in top 10: 99 (0)

Holders
105
Holders Change
+40
Holders Change %
+61.54%
% of All Funds
1.28%
Holding in Top 10
9
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
49
Increased
36
Reduced
9
Closed
8
Calls
$22.1M
Puts
$295K
Net Calls
+$21.8M
Net Calls Change
+$14.9M
Name Holding Trade Value Shares
Change
Change in
Stake
MVM
1
Medicxi Ventures Management
Jersey
$94.6M
TCM
2
TCG Crossover Management
California
$87.5M +$29.4M +946,133 +58%
FIS
3
FCPM III Services
Netherlands
$62.1M +$46.2M +1,489,096 +433%
O
4
OrbiMed
New York
$55.6M +$17.3M +556,273 +51%
RI
5
RTW Investments
New York
$55.5M +$5.18M +166,666 +11%
FCMV
6
Foresite Capital Management VI
California
$52.9M
SL
7
Siren LLC
Connecticut
$46.6M +$24.7M +794,534 +137%
Vanguard Group
8
Vanguard Group
Pennsylvania
$40.2M +$15.2M +490,603 +70%
FLSM
9
Frazier Life Sciences Management
California
$33.3M +$30.5M +983,333 New
B
10
Braidwell
Connecticut
$31.5M +$28.9M +929,694 New
RG
11
Redmile Group
California
$30M +$10.4M +333,333 +60%
PA
12
Perceptive Advisors
New York
$28M +$19.9M +642,000 +349%
SCM
13
Soleus Capital Management
Connecticut
$25.9M +$7.02M +226,097 +42%
NCM
14
Nantahala Capital Management
Connecticut
$25.5M +$4.06M +130,871 +21%
IC
15
Ikarian Capital
Texas
$22.5M +$1.56M +50,271 +8%
CP
16
Caligan Partners
New York
$21.8M +$20M +644,400 New
State Street
17
State Street
Massachusetts
$21.7M +$18.7M +602,421 +1,611%
Citadel Advisors
18
Citadel Advisors
Florida
$20M +$17.9M +576,272 +3,711%
GPP
19
Great Point Partners
Connecticut
$19.7M +$18M +581,187 New
OCA
20
Octagon Capital Advisors
New York
$19.4M +$17.8M +574,000 New
ACM
21
ADAR1 Capital Management
Texas
$17.3M +$59.3K +1,908 +0.4%
BlackRock
22
BlackRock
New York
$16.5M +$12.3M +396,650 +443%
BCM
23
Boone Capital Management
Georgia
$15.9M -$9.69M -312,005 -40%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$14.4M +$11.8M +379,480 +836%
MB
25
MPM BioImpact
Massachusetts
$13.5M +$12.4M +397,906 New

RAPT Hedge Fund Activity: Q4 2025 in Review

105 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q4 2025, worth a combined $1.02B — up 139% from $428M a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new RAPT positions and 8 closed out — a net gain of 41 holders — while 36 added to existing stakes and 9 trimmed.

The largest buyer was FCPM III Services, adding an estimated $46.2M. The largest seller was Deep Track Capital, cutting an estimated $19.9M.

  • 105 institutional investors held RAPT Therapeutics (RAPT) as of Q4 2025, up from 65 in Q3 2025.
  • Funds reported $1.02B of RAPT Therapeutics stock for Q4 2025, up 139% quarter-over-quarter.
  • 49 funds opened new RAPT Therapeutics positions in Q4 2025 and 8 closed out, a net change of +41 holders.
  • The largest RAPT Therapeutics buyer in Q4 2025 was FCPM III Services, an estimated $46.2M added.
  • The largest RAPT Therapeutics seller in Q4 2025 was Deep Track Capital, an estimated $19.9M sold.

Based on aggregated 13F filings for Q4 2025.